Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label crossover PK and food-effect study of TAS-116 in advanced solid tumors
jRCT2080224130Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimitespib in Nonhematologic neoplasms (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Relative pharmacokinetics and bioavailability of TAS-116 Formulation A vs Formulation B under fasting conditions and Effect of a high-fat/high-calorie meal on TAS-116 pharmacokinetics and bioavailability (Formulation A). Started Nov 2018; status: completed.
02
Drugs
pimitespib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224130.